Skip to content

Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract

Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00544427
Enrollment
0
Registered
2007-10-16
Start date
2003-08-31
Completion date
2020-12-31
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorder of Upper Digestive Tract

Keywords

Upper Areo-Digestive tract

Brief summary

The Optical Coherence Tomography is a minimally-invasive diagnostic tool in both the office and operating room settings can identify sources of airway obstruction and effective surgical interventions. The researcher can use Optical Coherence Tomography to image tissues of the aero-digestive tract during surgical endoscopy in to the nose, oral cavity, larynx and ear in an outpatient clinic setting.

Detailed description

The Optical Coherence Tomography imaging system has low power non-laser broad band infrared light shine onto laryngeal, esophageal, tracheal, oral, nasal and ear tissue and does not involve input of significant amounts of energy and no temperature rise occurs. The gradual development and acceptance of Optical Coherence Tomography as an imaging modality serves as an alternative to invasive tissue biopsy as a diagnostic measure. Imaging diagnosis, can implement and more convenient than tissue biopsy and can reduce procedural complications.

Interventions

DEVICEOptical coherence tomography

Optical coherence tomography imaging

Sponsors

Children's Hospital of Orange County
CollaboratorOTHER
Beckman Laser Institute University of California Irvine
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male and female age from new born to all age

Exclusion criteria

* subject who do not sign consent form

Design outcomes

Primary

MeasureTime frame
Diagnostic toolup to 4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026